Revium Rx.
Revium Rx. (RVRC): 3 pipeline candidates · ~8 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
7.7 months
D/E 0.26 · 0% dilution
Lead: Preclinical
3 candidates
N/A
N/A
A transparent, data-derived signal for Revium Rx.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$101.4M
Cash
$920K
Quarterly Burn
$541K
Runway
7.7 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| liposomal protein-loaded technology | Preclinical |
| nano-candesartan | Preclinical |
| nano-mupirocin | Preclinical |
Frequently asked questions
How many drug candidates are in Revium Rx.'s pipeline?
Revium Rx. (RVRC) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Revium Rx.'s lead drug candidate?
Revium Rx.'s most advanced tracked candidate is liposomal protein-loaded technology (Preclinical) for immunization (including SARS-CoV-2).
What is Revium Rx.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Revium Rx. has approximately 7.7 months of cash runway.
What is Revium Rx.'s market capitalization?
Revium Rx.'s market capitalization is approximately $101.4M.
Who is the CEO of Revium Rx.?
Mr. Amir Avraham CPA is the chief executive officer of Revium Rx. (RVRC).
Get the full picture on Revium Rx.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.